Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nycomed GmbH
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
- Medical Devices
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bradley Pharmaceuticals, Guangdong Techpool Bio-Pharma Co., Ltd.